Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings.
2025 · 1st Quarter (Jan 1 - Mar 31)
ALKERMES, INC.
Filed by SPLITOAK STRATEGIES LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- SPLITOAK STRATEGIES LLC
- Client
- ALKERMES, INC.
- Filing UUID
- 6207fc70-134f-4117-a2c6-3b6c1102fac0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.